Article

FDA clears tablet-based ultrasound imaging system

The FDA has granted 510(k) clearance to Escalon Medical Corp.’s tablet-based ultrasound imaging system, the Sonomed Escalon VuPad.

 

Ardmore, PA-The FDA has granted 510(k) clearance to Escalon Medical Corp.’s tablet-based ultrasound imaging system, the Sonomed Escalon VuPad.

The device-which utilizes touch screen controls-combines Sonomed Escalon’s UBM and newly enhanced B-scan image quality with an ultra-high-resolution screen that has a 25% larger viewing area than other portable devices, according to the company. Proprietary enhanced focus rendering enables the device to capture both still images and high-resolution video clips that can be reviewed frame by frame.

“The new (imaging system) is a revolutionary portable ultrasound device that delivers exceptional image quality in a wide range of ophthalmic applications,” said Richard J. DePiano Jr., chief executive officer of Escalon Medical.

The device will be on display at the annual symposium and congress of the American Society of Cataract and Refractive Surgery in Boston April 25 through April 29.

 

The company said it is anticipating CE marking and clearance by other international regulatory bodies in the coming months.

“We are pleased by the initial indications and the long-term opportunity surrounding (the device) . . . however, we may experience sales fluctuations as we update our product offering,” added DePiano. “In addition, planned increases to research and development expenses, as well as increased sales and marketing costs could pressure financial results.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.